Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

June 17, 2020June 17, 2020

DalcA Shows Sustained Efficacy in Hemophilia B in Trial

News

Under-the-skin, preventive treatment with Dalcinonacog alfa (DalcA) led to sustained and protective levels of factor IX (FIX) in people with severe hemophilia B, final data from a Phase 2b trial ... Read more

May 6, 2020May 6, 2020

EU Patients Satisfied with Treatment and Physically Active, Survey Finds

News

Europeans with severe hemophilia are largely satisfied with available treatments and able to maintain active lives, according to a survey of healthcare professionals by the biopharmaceutical company Sobi. Results also ... Read more

May 4, 2020May 4, 2020

Prophylaxis Better Than On-demand Therapy for Reducing Bleeds in Hemophilia A, Study Reports

News

Switching from on-demand to preventive treatment — or prophylaxis — significantly reduces bleeding in adults with hemophilia A, including the elderly, a real-life study shows. The study, “Long‐term analysis ... Read more

April 17, 2020April 17, 2020

Blood Evident in Urine Linked to Hypertension in Patients with Family History

News

Blood visibly present in urine — called macroscopic hematuria — considerably increases the risk of hypertension in hemophilia patients with a family history of high blood pressure, and is not ... Read more

April 13, 2020April 13, 2020

Blood Type, Von Willebrand Factor Play No Role in FVIII Levels in Non-Severe Hemophilia A, Study Suggests

News

In contrast to observations in the general population, blood type and levels of von Willebrand factor (VWF) don’t appear to influence factor VIII (FVIII) levels in people with non-severe ... Read more

April 3, 2020April 3, 2020

Novo Nordisk Offers Assurances on Hemophilia Therapy Supplies, Aid to Patients

News

Novo Nordisk reports that its treatments for hemophilia and other disorders remain available, and it is taking measures to support patients during the current COVID-19 pandemic. The company has ... Read more

March 25, 2020March 25, 2020

FVIII Gene Therapy Directly into Joints May Best Protect Against Damage

News

Gene therapy delivering the blood clotting factor VIII (FVIII) — whose lack causes hemophilia A — into the joints did better at protecting against hemophilic arthropathy (joint damage) than did administration into ... Read more

March 13, 2020March 13, 2020

Kovaltry Safe and Effective Prophylactic for Hemophilia A, Long-term Study Shows

News

Preventive treatment with Kovaltry (octocog alfa) is safe and effective at preventing bleeds, including joint bleeds, for up to two years in people with hemophilia A, a long-term extension ... Read more

March 9, 2020March 9, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still ... Read more

February 17, 2020February 17, 2020

Light Chain, Takeda Reach Key Milestone in Partnership Developing Bispecific Antibodies for Treating Hemophilia A

News

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has completed the discovery phase of its collaborative program with Takeda for developing bispecific antibodies — protective proteins produced by ... Read more

Pin It on Pinterest